However, studies on long-term efficacy and safety of first generation SRLs demonstrated that only 30% to 40% of patients achieve normalization of predefined GH and IGF-1 levels during long-term treatment [125], even though a significant percentage of pituitary adenomas shows a variable degree of shrinkage during long-term SRL treatment. Here, GH1 is linked to pituitary gland adenoma.